A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-15 and is reviewed periodically as new material appears.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
In June 1973, Gaddafi created a political ideology as a basis for the Popular Revolution: Third International Theory. This approach regarded both the US and the Soviet Union as imperialist and thus rejected Western capitalism as well as Marxist–Leninist atheism. In this respect, it was similar to the Three Worlds Theory developed by China's political leader Mao Zedong. As part of this theory, Gaddafi praised nationalism as a progressive force and advocated the creation of a pan-Arab state which would lead the Islamic and Third Worlds against imperialism. Gaddafi saw Islam as having a key role in this ideology, calling for an Islamic revival that returned to the origins of the Qur'an, rejecting scholarly interpretations and the Hadith; in doing so, he angered many Libyan clerics. During 1973 and 1974, his government deepened the legal reliance on sharia, for instance by introducing flogging as punishment for those convicted of adultery or homosexual activity. Gaddafi summarized Third International Theory in three short volumes published between 1975 and 1979, collectively known as The Green Book. Volume one was devoted to the issue of democracy, outlining the flaws of representative systems in favour of direct, participatory GPCs. The second dealt with Gaddafi's beliefs regarding socialism, while the third explored social issues regarding the family and the tribe. While the first two volumes advocated radical reform, the third adopted a socially conservative stance, proclaiming that while men and women were equal, they were biologically designed for different roles in life.
== Biography == After migrating to America, Banki graduated from the University of California, Berkeley and subsequently earned a PhD in chemical engineering with a focus on biotechnology from Princeton University. He has published numerous scientific articles and a biotechnology book. After completing his PhD, he worked as a management consultant at the New York City office of McKinsey & Company. In January 2010, Banki was arrested and prosecuted by the United States Attorney's office in New York City. He was charged with violating US sanctions against Iran. He spent 22 months in prison before winning his case on appeal in the Second Circuit Court of Appeals, with all charges against him related to the sanctions being dismissed. After his release Banki earned a Master of Business Administration from the University of California, Los Angeles, and worked at NBCUniversal.
Dehydration is a common risk factor for exertional rhabdomyolysis because it causes a reduction of plasma volume during exertion. This leads to a reduction of blood flow through the vascular system which inhibits blood vessel constriction.
Chapter 8 of the 1977 Soviet Constitution is titled as the "Soviet Union is a union state". Article 70 stated that the union was founded on the principles of "socialist federalism" as a result of the free self-determination of nations and the voluntary association of equal Soviet Socialist Republics. Article 71 listed all fifteen union republics that united into the Soviet Union. According to Article 76 of the 1977 Soviet Constitution, a union republic was defined as a sovereign Soviet socialist state that had united with other Soviet Republics into the USSR. Article 78 of the Constitution stated that the territory of a union republic may not be altered without its consent. The boundaries between republics may be altered by mutual agreement of the republics concerned, if the rest of the union agreed. Article 81 of the Constitution stated that "the sovereign rights of Union Republics shall be safeguarded by the USSR". In the final decades of its existence, the Soviet Union officially consisted of fifteen Soviet Socialist Republics (SSRs). All of them, with the exception of the Russian SFSR (until 1990), had their own local party chapters of the All-Union Communist Party. In 1944, amendments to the All-Union Constitution allowed for separate branches of the Red Army for each Soviet Republic. They also allowed for Republic-level commissariats for foreign affairs and defense, allowing them to be recognized as de jure independent states in international law.
== Condensation polymerization == Step-growth polymerization and condensation polymerization are two different concepts, not always identical. In fact polyurethane polymerizes with addition polymerization (because its polymerization produces no small molecules), but its reaction mechanism corresponds to a step-growth polymerization. The distinction between addition polymerization and condensation polymerization was introduced by Wallace Carothers in 1929, and refers to the type of products, respectively:
Sources: en.wikipedia.org
The Ranger program, started in 1959 by NASA's Jet Propulsion Laboratory, aimed to conduct hard impacts on the Moon and had its first success in 1962, after three failures due to launch aborts (Ranger 1 and Ranger 2) and a failure to reach the Moon (Ranger 3), when the 730-pound (330 kg) Ranger 4 became the first US spacecraft to reach the Moon, but its solar panels and navigational system failed near the Moon and it impacted the far side without returning any scientific data. Ranger 5 ran out of power and missed the Moon by 725 kilometers (391 nmi) on October 21, 1962. The first successful Ranger mission was the 806-pound (366 kg) Block III Ranger 7 which impacted on July 31, 1964. Ranger had three successful impacts out of nine attempts. In 1963, the Soviet Union's "2nd Generation" Luna programme was less successful than the earlier Luna probes; Luna 4, Luna 5, Luna 6, Luna 7, and Luna 8 were all met with mission failures. However, in 1966 the Luna 9 achieved the first soft-landing on the Moon, and successfully transmitted photography from the surface. Luna 10 marked the first man-made object to establish an orbit around the Moon, followed by Luna 11, Luna 12, and Luna 14 which also successfully established orbits. Luna 12 was able to transmit detailed photography of the surface from orbit. Luna 10, 12, and Luna 14 conducted Gamma ray spectrometry of the Moon, among other tests. The Zond programme was orchestrated alongside the Luna programme with Zond 1 and Zond 2 launching in 1964, intended as flyby missions, however both failed.
The Kashmir conflict remains a major issue between Pakistan and India, with three of their four wars fought over it. Due partly to strained relations with India, Pakistan has close ties with Turkey and Iran, both focal points in its foreign policy. Saudi Arabia also holds importance in Pakistan's foreign relations. As a non-signatory of the Treaty on Nuclear Non-Proliferation, Pakistan holds influence in the IAEA. For years, Pakistan has blocked an international treaty to limit fissile material, arguing that its stockpile does not meet its long-term needs. Pakistan's nuclear program in the 20th century aimed to counter India's nuclear ambitions in the region, and reciprocal nuclear tests ensued after India's nuclear tests, solidifying Pakistan as a nuclear power. Pakistan maintains a policy of Full spectrum deterrence, considering its nuclear program vital for deterring foreign aggression.
=== Other === Flunitrazepam impairs cognitive functions. This may appear as lack of concentration, confusion and anterograde amnesia—the inability to create memories while under the influence. It can be described as a hangover-like effect which can persist to the next day. It also impairs psychomotor functions similar to other benzodiazepines and nonbenzodiazepine hypnotic drugs; falls and hip fractures were frequently reported. The combination with alcohol increases these impairments. Partial, but incomplete tolerance develops to these impairments. Other adverse effects include:
== Indications == Teicoplanin treats a wide range of infections with Gram-positive bacteria, including endocarditis, sepsis, soft tissue and skin infections, and venous catheter-associated infections. Studies have investigated the use of oral teicoplanin in the treatment of pseudomembranous colitis and Clostridioides difficile-associated diarrhea, finding it to demonstrate efficacy comparable to that of vancomycin.
Sources: en.wikipedia.org
As the world's population continues to grow, experts believe that current food supplies will not be able to supply the population. Thus, a sustainable food source is critical. Studies have shown that entomophagy, the consumption of insects, has the potential to sustain a growing population. Insects such as crickets require less feed, less water, and provide around the same amount of protein that chickens, cows, and pigs do. Crickets can be ground into a protein flour. In one study, researchers provide an overview of the process of 3D printing insect flour into foods that do not resemble insects; thus, keeping the nutritional value of the insect intact.
== Screening == Initial screening for CIP/CIM may be performed using an objective scoring system for muscle strength. The Medical Research Council (MRC) score is one such tool, and sometimes used to help identify CIP/CIM patients in research studies. The MRC score involves assessing strength in 3 muscle groups in the right and left sides of both the upper and lower extremities. Each muscle tested is given a score of 0–5, giving a total possible score of 60. An MRC score less than 48 is suggestive of CIP/CIM. However, the tool requires that patients be awake and cooperative, which is often not the case. Also, the screening tool is non-specific, because it does not identify the cause a person's muscle weakness. Once weakness is detected, the evaluation of muscle strength should be repeated several times. If the weakness persists, then a muscle biopsy, a nerve conduction study (electrophysiological studies), or both should be performed.
== Adverse events == The most common adverse events at the beginning of treatment are nausea and headache. More serious adverse events are peripheral neuropathy, which can occur in up to 33% of patients with advanced disease, oral ulcers, oesophageal ulcers and, rarely, pancreatitis.
== Net worth == In October 2017, Forbes listed Newell among the 100 wealthiest people in the United States, with an estimated net worth of $5.5 billion. In December 2021, Forbes estimated that Newell had a net worth of $3.9 billion and owned at least one quarter of Valve. According to Charlie Fish, the author of The History of Video Games, as of 2021 Newell was the richest person in the video game industry. In 2025, Forbes estimated that Newell owned at least half of Valve and had a net worth of $11 billion.
== January 6, 1982 (Wednesday) == Speaking at the annual meeting of the American Association for the Advancement of Science at Washington, Dr. James Hansen, a climatologist for NASA's Goddard Institute of Space Studies warned that the increase of carbon dioxide and other chemicals (such as methane and nitrous oxide) in Earth's atmosphere would cause a substantial warming of the Earth's climate during the 1980s, sooner than predictions that global warming would not take place until the 21st century. Serial murderer William G. Bonin, a 34-year old truck driver charged with being the "Freeway Killer", was convicted on charges of torturing and murdering 10 young men and boys from May 1979 until his capture on June 12, 1980. He was acquitted of charges of killing two other victims. Initially, he had been linked by investigators to 21 homicides, and indicted for 12. Born: Eddie Redmayne, English stage and film actor, winner of the 2014 Academy Award for Best Actor for his portrayal of Stephen Hawking in The Theory of Everything; in Westminster, London Died: Shang Yue, 79, Chinese Marxist economic historian and fiction author who was purged in 1958 but rehabilitated in 1976 Bill Crawford, 68, American editorial cartoonist
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.